Abeona Therapeutics: Kaufman reports 7.3% stake
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
ABEONA THERAPEUTICS INC. (ABEO) is the issuer whose common stock Daniel Kaufman, identified as an individual investor, reported beneficially owning 4,159,099 shares, or 7.3% of the class, as of September 30, 2026. He reported sole voting and dispositive power over all 4,159,099 shares, with zero shared voting or dispositive power.
Key Figures
Key Terms
Beneficially Owned regulatory
Sole Voting Power regulatory
Sole Dispositive Power regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.